Clinical trial · Observational
Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
NCT00660803CI-TRIAL-00003051completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Characterize the demographic and clinical features, as well as the main treatment results, among patients with advanced breast cancer treated with fulvestrant in Brazil.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fulvestrant | Drug | Fulvestrant | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.
- interventionNames
- Drug: Fulvestrant
Primary outcomes (2)
- measure
- Time to tumour progression
- measure
- Objective response
Secondary outcomes (3)
- measure
- Duration of treatment with fulvestrant
- measure
- Time and duration of response
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Positive HR or ER by immunohistochemistry * Postmenopausal status at the time of treatment with fulvestrant * Failure of at least one previous endocrine therapy before treatment with fulvestrant. Exclusion Criteria: * Patients who are still undergoing treatment with fulvestrant will not be eligible to participate in the study
References
Publications (0)
Data not yet available
No reference posted for this study.